We are live on !
Find out more
Jim Simons Renaissance Technologies
AUM
$73.4B
Turnover
30.34%
1-Year Est. Return
32.8%
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
This Fund
S&P 500
This Quarter Est. Return
+10.43%
1 Year Est. Return
+32.8%
3 Year Est. Return
+177.41%
5 Year Est. Return
+184.82%
10 Year Est. Return
+833.33%
AUM
$66.5B
AUM Growth
+$7.54B
(+13%)
Cap. Flow
+$3.2B
Cap. Flow % of AUM
Cap. Flow %
4.81%
Top 10 Holdings %
Top 10 Hldgs %
11.06%
Holding
4,024
New
578
Increased
1,558
Reduced
1,325
Closed
537
Avg Time Held
3.2
years
Top 10 Avg Time Held
2
years
Top 20 Avg Time Held
2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$533M |
| 2 |
Apple
AAPL
|
+$347M |
| 3 |
Micron Technology
MU
|
+$272M |
| 4 |
Eli Lilly
LLY
|
+$232M |
| 5 |
Super Micro Computer
SMCI
|
+$185M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$472M |
| 2 |
NVIDIA
NVDA
|
+$413M |
| 3 |
Tesla
TSLA
|
+$403M |
| 4 |
Coinbase
COIN
|
+$236M |
| 5 |
Johnson & Johnson
JNJ
|
+$224M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.64% |
| 2 | Healthcare | 16.8% |
| 3 | Consumer Discretionary | 13.04% |
| 4 | Industrials | 9.65% |
| 5 | Financials | 9.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Palantir
PLTR
$404B
| $1.43B | 2.15% |
38,419,240
-1,096,069
| -3% | -$33.6M |
2021 Q2
13 quarters
|
|
2
Novo Nordisk
NVO
$183B
| $975M | 1.47% |
8,189,315
-976,059
| -11% | -$130M |
2013 Q2
45 quarters
|
|
3
United Therapeutics
UTHR
$25.2B
| $772M | 1.16% |
2,155,392
-19,300
| -0.9% | -$6.52M |
2013 Q2
45 quarters
|
|
|
4
Apple
AAPL
$5.2T
| $763M | 1.15% |
3,276,203
+1,554,759
| +90% | +$347M |
2020 Q3
16 quarters
|
|
5
Vertex Pharmaceuticals
VRTX
$137B
| $759M | 1.14% |
1,631,493
+65,105
| +4% | +$31.3M |
2017 Q1
30 quarters
|
|
|
6
Microsoft
MSFT
$3.9T
| $676M | 1.02% |
1,571,271
+1,246,346
| +384% | +$533M |
2024 Q2
1 quarter
|
|
7
VeriSign
VRSN
$28B
| $603M | 0.91% |
3,175,990
+148,294
| +5% | +$26.7M |
2013 Q2
45 quarters
|
|
8
Sprouts Farmers Market
SFM
$4.79B
| $490M | 0.74% |
4,440,644
+2,500
| +0.1% | +$238K |
2016 Q2
33 quarters
|
|
9
Airbnb
ABNB
$109B
| $459M | 0.69% |
3,616,495
+215,090
| +6% | +$27.9M |
2021 Q2
13 quarters
|
|
|
10
NVIDIA
NVDA
$3.89T
| $428M | 0.64% |
3,528,071
-3,493,719
| -50% | -$413M |
2023 Q1
6 quarters
|
|
11
Exelixis
EXEL
$16.9B
| $399M | 0.6% |
15,359,916
+196,850
| +1% | +$4.89M |
2016 Q3
32 quarters
|
|
12
Franco-Nevada
FNV
$47.9B
| $390M | 0.59% |
3,138,549
+64,600
| +2% | +$8M |
2014 Q1
42 quarters
|
|
13
Cboe Global Markets
CBOE
$39.3B
| $385M | 0.58% |
1,879,724
+5,000
| +0.3% | +$982K |
2013 Q2
45 quarters
|
|
14
Fortinet
FTNT
$93.2B
| $383M | 0.58% |
4,943,162
-83,232
| -2% | -$5.69M |
2015 Q3
36 quarters
|
|
15
Meta Platforms (Facebook)
META
$1.63T
| $371M | 0.56% |
647,424
-398,709
| -38% | -$205M |
2021 Q3
12 quarters
|
|
16
Gilead Sciences
GILD
$209B
| $351M | 0.53% |
4,188,524
-869,074
| -17% | -$66.3M |
2014 Q4
39 quarters
|
|
17
Allison Transmission
ALSN
$10.3B
| $329M | 0.49% |
3,423,419
-99,100
| -3% | -$8.5M |
2013 Q3
44 quarters
|
|
18
monday.com
MNDY
$3.23B
| $316M | 0.48% |
1,138,290
+15,600
| +1% | +$3.86M |
2021 Q4
11 quarters
|
|
19
DoorDash
DASH
$75.1B
| $312M | 0.47% |
2,186,688
-601,155
| -22% | -$72.9M |
2021 Q2
13 quarters
|
|
20
CME Group
CME
$114B
| $310M | 0.47% |
1,403,089
+784,500
| +127% | +$162M |
2021 Q3
12 quarters
|
|
21
Corcept Therapeutics
CORT
$7.88B
| $301M | 0.45% |
6,509,002
-403,569
| -6% | -$14.3M |
2015 Q1
38 quarters
|
|
22
Netflix
NFLX
$256B
| $298M | 0.45% |
4,202,090
+1,485,090
| +55% | +$99.3M |
2024 Q2
1 quarter
|
|
23
Incyte
INCY
$24.5B
| $297M | 0.45% |
4,499,540
-718,797
| -14% | -$45.8M |
2017 Q4
27 quarters
|
|
24
Neurocrine Biosciences
NBIX
$16.9B
| $297M | 0.45% |
2,574,546
+106,400
| +4% | +$14.6M |
2018 Q4
23 quarters
|
|
25
Wingstop
WING
$4.29B
| $291M | 0.44% |
699,146
+96,156
| +16% | +$37.4M |
2023 Q1
6 quarters
|
|
Similar funds
Jim Simons's Q3 2024 Portfolio in Review
As of Q3 2024, Jim Simons held 4,024 positions worth $66.5B, up 13% from $59B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Jim Simons deployed $3.2B of net new capital in Q3 2024, opening 578 new positions and adding to 1,558 existing holdings. Its largest new stake was Micron Technology: 2,604,914 shares worth $270M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 20% a quarter earlier, followed by Healthcare and Consumer Discretionary.
On the sell side, the largest reduction was NVIDIA, an estimated $413M trimmed.
- Jim Simons's largest Q3 2024 buy was Micron Technology: 2,604,914 shares worth $270M.
- Jim Simons added most to Microsoft in Q3 2024, an estimated $533M increase.
- Jim Simons's biggest Q3 2024 reduction was NVIDIA, cutting an estimated $413M.
- Jim Simons fully exited Broadcom in Q3 2024, selling an estimated $472M.
- Jim Simons's ten largest holdings make up 11% of its $66.5B portfolio in Q3 2024.
- Jim Simons opened 578 new positions and closed 537 in Q3 2024.
- Jim Simons's portfolio value rose 13% quarter-over-quarter to $66.5B.
Based on Renaissance Technologies's 13F filing for Q3 2024, filed 13 Nov 2024.